Zentalis Pharmaceuticals Files 2024 10-K

Ticker: ZNTL · Form: 10-K · Filed: Mar 26, 2025 · CIK: 1725160

Sentiment: neutral

Topics: 10-K, pharmaceuticals, annual-report

TL;DR

Zentalis filed its 2024 10-K. Financials and biz details out.

AI Summary

Zentalis Pharmaceuticals, Inc. filed its 2024 10-K on March 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is based in San Diego, CA. Key financial data and operational details for the fiscal year 2024 are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Zentalis Pharmaceuticals' financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Zentalis faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Zentalis Pharmaceuticals' primary business focus?

Zentalis Pharmaceuticals, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

When did Zentalis Pharmaceuticals, Inc. file its 10-K report?

Zentalis Pharmaceuticals, Inc. filed its 10-K report on March 26, 2025.

What fiscal year does this 10-K filing cover?

This 10-K filing covers the fiscal year ending December 31, 2024.

Where is Zentalis Pharmaceuticals, Inc. located?

Zentalis Pharmaceuticals, Inc. is located in San Diego, CA, with its business address at 10275 Science Center Drive, Suite 200.

What were Zentalis's previous company names?

Zentalis Pharmaceuticals, Inc. was formerly known as Zentalis Pharmaceuticals, LLC (name change effective 20200107) and prior to that, Zeno Pharma, LLC (name change effective 20171212).

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 26, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing